Lenalidomide is a drug, administered as a tablet, which affects the activity of the immune system and may impact the growth and spread of cancer cells. An ongoing phase III clinical trial explores whether offering it together with rituximab (an antibody) could be a viable therapy option for patients who have not had any prior treatment for their follicular lymphoma. Currently most of these patients would receive rituximab in combination with chemotherapy.
Lenalidomide (Revlimid) in combination with rituximab for untreated follicular lymphoma
